Market Cap
$335.0M
CCCC
C4 Therapeutics, Inc.
$3.03 ▼ -3.66%
Prev close $3.14Market cap$335.0M
12-mo target$13.33 (+341.5%)
High Impact Filing (7/10)28 New Institutional Positions14 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on CCCC right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Inst. Holders
50 funds
Inst. Value
$356.0M
Inst. Activity
28 buys / 14 sells
Social Sentiment
50° Neutral
SEC Reports
9
Press Releases
3
Price chart 30d -20.2%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 25, 2026 fda
C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting
Immunomodulatory Effects of Cemsidomide with Dexamethasone from Phase 1 Trial Demonstrated Robust T-
Sep 18, 2026 Insider
Adams Kendra acquired via exercise 6,250 shares
Chief Financial Officer
Sep 18, 2026 Insider
Aug 15, 2026 SEC Adams Kendra surrendered for taxes 2,775 shares
Chief Financial Officer @ $3.39 ($9.4K)
Jay L. Geldmacher, a former REZI CEO and reporting owner of C4 Therapeutics, filed a Form 144 notice of intent to sell a
144 — Impact 3/10
Eight major institutional investors, including BlackRock, State Street, and Fidelity, more than doubled their C4 Therape
INST-CLUSTER — Impact 6/10
C4 Therapeutics reported Q2 2026 revenue of $6.6M (up 2.7% YoY) and a net loss of $23.6M ($0.18 per share), beating the
8-K — Impact 5/10
Jul 10, 2026 Insider
REYNO LEONARD acquired via exercise 15,325 shares
Chief Medical Officer
Jun 30, 2026 Inst.
BlackRock, Inc. — DOUBLED
7,896,718 shares ($36.9M)
Analyst ratings buy % -1.1%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Jun 1, 2026 | Evercore ISI Group | MAINTAIN | Outperform | 59% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 4 | 8 | 1 | 0 | 0 | 92% | |
| Aug 1, 2026 | 4 | 8 | 1 | 0 | 0 | 92% | |
| Jul 1, 2026 | 4 | 8 | 1 | 0 | 0 | 92% | |
| Jun 1, 2026 | 5 | 8 | 1 | 0 | 0 | 93% | |
| May 1, 2026 | 5 | 8 | 1 | 0 | 0 | 93% | |
| Apr 1, 2026 | 5 | 8 | 1 | 0 | 0 | 93% | |
| Mar 1, 2026 | 5 | 8 | 1 | 0 | 0 | 93% | |
| Feb 1, 2026 | 5 | 8 | 1 | 0 | 0 | 93% |
Price targets
Where 6 covering analysts think CCCC trades over the next 12 months.
$13.33 +341.5% upside Strong Buy
Current$3.02 Low$7.00 Median$11.00 High$30.00 6 analysts
$7.00$30.00
Analyst rating Strong Buy· 1.1/5 as of Oct 2, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
50°
Neutral
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
9 SEC filing reports analyzed · 4 bullish, 0 bearish, 1 mixed, 4 neutral · avg impact 5.0/10.Plus 3 press releases.
NEUTRAL1443/10
Jay L. Geldmacher, a former REZI CEO and reporting owner of C4 Therapeutics, filed a Form 144 notice
Aug 15, 2026
BULLISHINST-CLUSTER6/10
Eight major institutional investors, including BlackRock, State Street, and Fidelity, more than doub
Aug 14, 2026
NEUTRAL8-K5/10
C4 Therapeutics reported Q2 2026 revenue of $6.6M (up 2.7% YoY) and a net loss of $23.6M ($0.18 per
Aug 11, 2026
NEUTRAL8-K2/10
C4 Therapeutics disclosed the departure of Chief Accounting Officer Mark Mossler, effective May 15,
May 15, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 25, 2026
fda
C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting
Immunomodulatory Effects of Cemsidomide with Dexamethasone from Phase 1 Trial Demonstrated Robust T-cell Activation, a Key Component of Cemsidomide’s
Sep 14, 2026
short_volume
Short Volume: CCCC — 57.4% short (0.3M / 0.5M)
Short: 288,376 | Exempt: 14,475 | TRF Vol: 501,982 | Short Ratio: 57.4% | Off-exchange volume (dark pool + OTC)
Sep 8, 2026
short_volume
Short Volume: CCCC — 72.3% short (0.7M / 1.0M)
Short: 749,530 | Exempt: 0 | TRF Vol: 1,036,606 | Short Ratio: 72.3% | Off-exchange volume (dark pool + OTC)
Sep 4, 2026
short_volume
Short Volume: CCCC — 74.8% short (0.9M / 1.2M)
Short: 916,266 | Exempt: 0 | TRF Vol: 1,224,641 | Short Ratio: 74.8% | Off-exchange volume (dark pool + OTC)
Sep 2, 2026
short_volume
Short Volume: CCCC — 59.5% short (0.4M / 0.7M)
Short: 404,407 | Exempt: 0 | TRF Vol: 679,323 | Short Ratio: 59.5% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.22 | $-0.25–$-0.20 | 24.7% | +0.0% | 3↑ 0↓ | $0.0B | 4 |
| Next Q | $-0.27 | $-0.32–$-0.22 | -51.4% | +0.0% | 1↑ 1↓ | $0.0B | 4 |
| Current FY | $-0.89 | $-0.96–$-0.80 | 22.2% | +0.0% | 3↑ 0↓ | $0.0B | 4 |
| Next FY | $-1.00 | $-1.11–$-0.85 | -12.7% | +0.0% | 2↑ 1↓ | $0.0B | 4 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.223 | — |
| 7d ago | $-0.223 | — |
| 30d ago | $-0.223 | — |
| 60d ago | $-0.253 | +0.030 |
| 90d ago | $-0.253 | +0.030 |
Institutional ownership
Which big funds own CCCC (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $356.0M total value (76,563,472 shares) as of 2026-Q2. Top holders: MORGAN, RA, BlackRock,. Net buying activity: 28 institutions added/increased vs 14 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| MORGAN STANLEY | 8,867,338 | $41.4M | 11.6% | — |
| RA CAPITAL MANAGEMENT, L.P. | 8,000,000 | $37.4M | 10.5% | — |
| BlackRock, Inc. | 7,896,718 | $36.9M | 10.4% | DOUBLED +285.5% |
| JPMORGAN CHASE & CO | 4,747,424 | $20.7M | 5.8% | ADD +47.3% |
| VANGUARD CAPITAL MANAGEMENT LLC | 4,417,731 | $20.6M | 5.8% | — |
| CITADEL ADVISORS LLC | 4,187,580 | $19.6M | 5.5% | ADD +66.8% |
| GOLDMAN SACHS GROUP INC | 3,530,991 | $16.5M | 4.6% | ADD +47.9% |
| WASATCH ADVISORS LP | 3,522,644 | $16.5M | 4.6% | TRIM -31.8% |
| TWO SIGMA INVESTMENTS, LP | 3,469,707 | $16.2M | 4.6% | — |
| BANK OF AMERICA CORP /DE/ | 2,656,359 | $12.4M | 3.5% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | DOUBLED | 2,048,526 | 7,896,718 | +285.5% | $36.9M |
| JPMORGAN CHASE & CO | ADD | 3,223,054 | 4,747,424 | +47.3% | $20.7M |
| CITADEL ADVISORS LLC | ADD | 2,511,015 | 4,187,580 | +66.8% | $19.6M |
| GOLDMAN SACHS GROUP INC | ADD | 2,387,378 | 3,530,991 | +47.9% | $16.5M |
| GEODE CAPITAL MANAGEMENT, LLC | DOUBLED | 951,043 | 2,522,163 | +165.2% | $11.8M |
| STATE STREET CORP | DOUBLED | 382,973 | 2,115,621 | +452.4% | $9.9M |
| D. E. Shaw & Co., Inc. | ADD | 1,060,331 | 1,740,989 | +64.2% | $8.1M |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | ADD | 1,286,840 | 1,732,210 | +34.6% | $8.1M |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 2,461,815 | 1,189,828 | -51.7% | $5.6M |
| DIMENSIONAL FUND ADVISORS LP | DOUBLED | 442,518 | 1,188,507 | +168.6% | $5.5M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
10 insiders, 17 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 18, 2026 | Adams Kendra | Chief Financial Officer | EXERCISE | 6,250 | — | — |
| Sep 18, 2026 | Adams Kendra | Chief Financial Officer | TAX W/H | 2,775 | $3.39 | $9.4K |
| Jul 10, 2026 | REYNO LEONARD | Chief Medical Officer | EXERCISE | 15,325 | — | — |
| Jul 10, 2026 | REYNO LEONARD | Chief Medical Officer | TAX W/H | 7,397 | $4.06 | $30.0K |
| Jul 1, 2026 | Anderson Kenneth Carl | Director | AWARD | 2,650 | $4.34 | $11.5K |
| Jul 1, 2026 | GROGAN DONNA ROY | Director | AWARD | 3,341 | $4.34 | $14.5K |
| Jun 24, 2026 | Koppikar Utpal | Director | AWARD | 62,000 | — | — |
| Jun 24, 2026 | GROGAN DONNA ROY | Director | AWARD | 62,000 | — | — |
| Jun 24, 2026 | Fawell Stephen | Director | AWARD | 62,000 | — | — |
| Jun 24, 2026 | Bessen Laura | Director | AWARD | 62,000 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for CCCC.
Shares short
40,189,287
Settlement Sep 15, 2026
Change vs prior
+7.4%
Semi-monthly cycle
Days to cover
22.7
At avg daily volume
Of shares outstanding
≈32.7%
Estimate — not % of float
All CCCC filing & press-release reports (12)
- 144 reportAug 15, 2026
- INST-CLUSTER reportAug 14, 2026
- 8-K reportAug 11, 2026
- PRESS-RELEASE reportJun 11, 2026
- 8-K reportMay 15, 2026
- 8-K reportMay 12, 2026
- PRESS-RELEASE reportMay 12, 2026
- 8-K reportApr 9, 2026
- PRESS-RELEASE reportApr 9, 2026
- PRESS-RELEASE reportMar 25, 2026
- INST-CLUSTER reportFeb 28, 2026
- 8-K reportFeb 26, 2026